CIPO Patents = 2 (Patent Applications = 3)

EPO Patents = 3 (Patent Applications = 3)

Average Co-Inventor Count = 3.1

ph-index = 2

Forward Citations = 6(Granted Patents)

Company Filing History:

5 out of 44

Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw

Katholieke Universiteit Leuven, Ku Leuven R&d

patents

5. 1 out of 184

Vrije Universiteit Brussel

patents

where one patent can have more than one assignee

Years Active: 2004-2021

Loading Chart...

9 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 11001624 - TSLP inhibitors (2021-05-11),

2. 10703799 - IL-33R and IL-1RAcP fusion proteins (2020-07-07),

3. 8309523 - Inhibitors of MALT1 proteolytic activity and uses thereof (2012-11-13),

4. 7893026 - Treatment of EGFR-dependent tumors by ABIN (a20 -binding inhibitor of NF kappab) (2011-02-22),

5. 7414026 - Inhibitors of NF-kappaB activation (2008-08-19),

6. 7122656 - Splice variant of MyD88 and uses thereof (2006-10-17),

7. 7094756 - Abin-mediated hepatitis protection (2006-08-22),

8. 6764852 - Internal ribosome entry site, vector containing same and uses thereof (2004-07-20),

9. 6673897 - Inhibitors of NF-&kgr;B Activation (2004-01-06),

Title: Rudi Beyaert: Innovator in Biotechnological Advancements

Introduction

Rudi Beyaert is a prominent inventor based in Zingem, Belgium. He has made significant contributions to the field of biotechnology, particularly in the development of therapeutic proteins. With a total of nine patents to his name, Beyaert's work focuses on innovative solutions for various medical conditions.

Latest Patents

Among his latest patents, Beyaert has developed TSLP inhibitors. This invention relates to monomeric fusion proteins that comprise the extracellular part of the thymic stromal lymphopoietin receptor (TSLPR) and the extracellular part of the interleukin-7 receptor alpha (IL-7Ralpha). These proteins serve as inhibitors of thymic stromal lymphopoietin (TSLP) activity. The invention further explores the use of these inhibitors as a medicament in the treatment of inflammatory diseases, cancer, and fibrosis. Another notable patent involves IL-33R and IL-1RAcP fusion proteins. This invention focuses on novel inhibitors of IL-33, specifically a fusion protein of the soluble IL-33 receptor with the soluble IL-1RAcP. This inhibitor is intended for the treatment of IL-33-related diseases such as asthma, atopic dermatitis, and psoriasis.

Career Highlights

Beyaert has worked with esteemed organizations, including the Flemish Interuniversity Institute for Biotechnology and Ghent University. His career reflects a commitment to advancing biotechnological research and developing innovative therapeutic solutions.

Collaborations

Throughout his career, Beyaert has collaborated with notable colleagues, including Karen Heyninck and Walter C. Fiers. These partnerships have contributed to the success of his research and the development of his patents.

Conclusion

Rudi Beyaert's contributions to biotechnology through his innovative patents highlight his role as a leading inventor in the field. His work continues to pave the way for advancements in medical treatments and therapeutic applications.

This text is generated by artificial intelligence and may not be accurate.